Conditions: Dyskinesia Levodopa-Induced Dyskinesia (LID) Parkinson's Disease (PD)
Keywords: Levodopa-Induced Dyskinesia LID Parkinsonism Parkinson's Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 77
Healthy volunteers: no

Brief summary:
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once nightly at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). The novel pharmacokinetic profile of ADS-5102 is expected to achieve i) maximal concentrations in the early morning through mid-day, when LID can be troublesome, and ii) lower concentrations in the evening, potentially reducing the negative impact of amantadine on sleep. This pharmacokinetic profile could enable higher doses to be tolerated with a once-nightly ER formulation than can be tolerated with an immediate-release formulation. The once-nightly dosing regimen may also provide enhanced convenience and compliance.

In a previous clinical study, ADS-5102 met its primary endpoint; LID was significantly reduced as measured by the change in UDysRS score over 8 weeks vs. placebo.

Detailed description:

Arms:
arm 1: ADS-5102 (amantadine HCl extended release) arm 2: Placebo

Interventions: intervention 1: ADS-5102 intervention 2: Placebo
Intervention descriptions: intervention 1: Oral capsules to be administered once nightly at bedtime, for 13 weeks. intervention 2: Oral capsules to be administered once nightly at bedtime, for 13 weeks.

Protocol document: